Glenmark Pharmaceuticals has informed that it has attached media release on 16th February 2021 titled ‘Glenmark launches SUTIB (Sunitinib)-priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%’ which is self?explanatory.
The above information is a part of company’s filings submitted to BSE.